Related Experiment Video
Updated: Aug 8, 2026
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Prerequisites for the immunotherapy of cancer
G Pawelec1, A Engel, M Adibzadeh
1Tübingen Ageing and Tumour Immunology Group, Second Department of Internal Medicine, University of Tübingen Medical School, Germany. graham.pawelec@med.uni-tuebingen.de
Abstract:
Tumours express proteins not commonly found in normal cells, or over-express certain proteins. These may in some cases serve as target antigens for immunological attack. It is therefore essential to improve our understanding of the nature of these target epitopes and the cells which recognize them, in order to develop immunotherapy as a realistic treatment for cancer. A small group of around 40 investigators recently came together at the Heinrich Fabri Institute of the University of Tübingen to discuss the identification of human tumour antigens and the exploitation of this knowledge for effective immunotherapy.
Insights
Identifying unique tumour antigens is key for developing effective cancer immunotherapy. Understanding these targets and the immune cells that recognize them is crucial for advancing cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Tumours exhibit unique or over-expressed proteins, known as target antigens.
- These antigens present potential targets for therapeutic immunological attack.
- Understanding these antigens is vital for developing effective cancer immunotherapies.
Purpose of the Study:
- To discuss the identification of human tumour antigens.
- To explore the exploitation of tumour antigens for effective cancer immunotherapy.
- To advance the understanding of target epitopes and recognizing immune cells.
Main Methods:
- A workshop involving approximately 40 investigators.
- Discussions focused on the identification and characterization of tumour antigens.
- Exploration of strategies for leveraging this knowledge in immunotherapy.
Main Results:
- Consensus on the importance of identifying tumour-specific antigens.
- Highlighting the need for further research into epitope structure and immune cell recognition.
- Emphasis on the potential of immunotherapy as a viable cancer treatment.
Conclusions:
- Further investigation into human tumour antigens is essential.
- Developing effective immunotherapy requires a deep understanding of antigen-epitope interactions.
- Translating this knowledge into clinical practice can lead to realistic cancer treatments.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...